top of page
About Us
Based on the cutting-edge technology, we are ahead ofthe next generation molecular diagnostic market.
History
2020
- COVID-19 RT-PCR PNA kit FDA EUA Approval
- COVID-19 Diagnostic kit CE-IVD Approval
- ISO 13485 Approval
- GMP IVD diagnostic devices Registration (medical device grade 3)
*Bio safety management grade 2
2021~
- Developing a Companion diagnostic reagent for lung cancer.
- Digital PCR Platform, Awarded Korea’s Top 10 Nano technology
- Digital PCR Platform NEP(New Excellent Product) Registration
- Digital PCR Platform Launch : Drop Generator, Analyzer(Reader), Oil, Premix, Cartridge, etc.
- Changed Company name (TNS Co., Ltd. → BioTNS Co., Ltd.)
2019
- Establishment of Molecular Diagnostic System Production Line
- Establishment of Diagnostic Kit Production Line
2018
- Integrated fully automatic gene discrimination facility
- Mitochondrial DNA SNP Analysis Method (National Forensic Service)
- How to determine the origin of domestic and foreign products (National Agricultural Products Quality Management Service)
2017
- GMP(KTC-AAB-17001) acquisition
2016
- Transfer of Polymeric Casting Technology
- Any Lab Assembly Microfluidic Chip Patent Registration
2015
- Venture Business Registration (No. 10-1628777)
2014
- Establishment of an affiliated research institute
- Lab-on-a-chip and ultrasonic fusion technology transfer
- Microfluidic flow block technology transfer
2013
- Next-generation biochip technology commercialization agreement (NNFC)
2011
- company establishment
bottom of page